WOW! @McdevittDamien Aspen Neuroscience colleagues announces $147.5M (!!!) in Series B financing to help fund clinical trials of the company’s 1st iPSC-derived autologous dopamine neuron replacement for #Parkinsons
Aspen Neuroscience announces $147.5M fina... - Cure Parkinson's
Aspen Neuroscience announces $147.5M financing to fund trials of the company’s 1st iPSC-derived autologous dopamine neuron replacement
Read more about...
1 Reply
•
Progress. Although still no date for a trial to actually start, never mind end
Not what you're looking for?
You may also like...
Aspen Neuroscience Trial - Autologous Neuronal Cell Replacement
-phase-12a-clinical-trial-of-autologous-neuronal-cell-replacement-therapy-for-parkinsons-disease-302
Aspen FINALLY Moving forward with Stem Cell Trials
Administration (FDA) has given Aspen Neuroscience clearance to launch a clinical trial of ANPD001,...
Covid 19 may infect dopamine neurons
article is in Neuroscience News and I guess this did not seem surprising to me...
Good News - Drugs to address chronic inflammation and PD - NodThera
NT-0796, and provides an update on the Company’s priority clinical development programme....
Big pharma never rest. A sad tale of corporate greed run amok.
consumers grasped until a series of baby-powder cases began to go to trial was that, for decades,...
Related Posts
Annovis Bio Buntanetap Interim Analysis of the Parkinson's Clinical Study
Zhittya announces \"Safe and Effective\" treatment for PD
“Scientists discover signalling circuit boards inside body's cells.” by University of Edinburgh
Parkinson’s and vagal nerve stimulation, promising human studies.
COULD PROBIOTICS HELP? PXN 21
